Immunotherapy combinations will be the focus – but attention is shifting towards these agents proving their overall survival benefits.
Roche rival has Breakthrough Therapy status.
Alecensa part of Roche’s goal of becoming dominant player in NSCLC
Approval by May could put Keytruda in pole position
A decisive moment in lung cancer treatment is nearing
BMS and Nektar’s combination latest in frenzied immunotherapy field